Innovent Biologics (SEHK:1801) - Aktienkurs, Nachrichten und Analyse

1801 Aktienübersicht

1801 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	5/6
Künftiges Wachstum	5/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	4/6
Dividenden	0/6

Belohnungen

68.3% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 58.72% pro Jahr

Die Erträge sind in den letzten 5 Jahren um 19.1% pro Jahr gestiegen.

Analysten sind sich einig, dass der Aktienkurs um 47%

Risikoanalyse

Signifikante Insiderverkäufe in den letzten 3 Monaten

Innovent Biologics, Inc. Wettbewerber

Sichuan Kelun-Biotech Biopharmaceutical

SEHK:6990

HK$37.4b

Shanghai Haohai Biological Technology

SEHK:6826

HK$13.9b

RemeGen

SEHK:9995

HK$16.1b

Akeso

SEHK:9926

HK$64.8b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Innovent Biologics
Historische Aktienkurse
Aktueller Aktienkurs	HK$37.00
52-Wochen-Hoch	HK$52.15
52-Wochen-Tief	HK$28.30
Beta	0.25
11 Monat Veränderung	-15.53%
3 Monate Veränderung	-14.84%
1 Jahr Veränderung	-15.43%
33 Jahre Veränderung	-49.66%
5 Jahre Veränderung	35.04%
Veränderung seit IPO	123.16%

Aktuelle Nachrichten und Updates

Recent updates

Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

Jun 14

Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 01

There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump

Feb 28

Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?

Jan 12

Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues

Dec 25

An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued

Sep 11

Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?

Jun 04

Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price

May 14

Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate

Dec 27

Aktionärsrenditen

	1801	HK Biotechs	HK Markt
7D	-0.5%	-0.3%	-0.6%
1Y	-15.4%	-15.2%	9.6%

Rendite im Vergleich zur Industrie: 1801 wie die Branche Hong Kong Biotechs , die im vergangenen Jahr eine Rendite von -15.2 erzielte.

Rendite vs. Markt: 1801 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von 9.6 erzielte.

Preisvolatilität

Is 1801's price volatile compared to industry and market?
1801 volatility
1801 Average Weekly Movement	8.6%
Biotechs Industry Average Movement	10.9%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.2%
10% least volatile stocks in HK Market	4.3%

Stabiler Aktienkurs: 1801 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: 1801Die wöchentliche Volatilität (9%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2011	5,263	Michael Yu	www.innoventbio.com

Innovent Biologics, Inc. ist ein biopharmazeutisches Unternehmen, das monoklonale Antikörper und andere Arzneimittel in den Bereichen Onkologie, Augenheilkunde, Autoimmun-, Herz-Kreislauf- und Stoffwechselerkrankungen in der Volksrepublik China entwickelt und vermarktet. Das Unternehmen bietet Tyvyt, einen humanen monoklonalen Anti-PD-1-Antikörper, BYVASDA, einen vollständig humanen monoklonalen Anti-VEGF-Antikörper, HALPRYZA, einen rekombinanten chimären monoklonalen Anti-CD20-Antikörper aus Maus und Mensch; SULINNO, ein vollständig humaner monoklonaler Anti-TNF-a-Antikörper; Pemazyre, ein selektiver FGFR-Inhibitor; Olverembatinib, ein neuartiger BCR-ABL-TK; Cyramza, ein VEGF-Rezeptor-2-Antagonist; und Retsevmo, ein selektiver und potenter RET-Kinase-Inhibitor. Das Unternehmen entwickelt außerdem IBI-326, eine vollständig humane BCMA-CAR-T-Zelltherapie; IBI-376, einen oralen Inhibitor von PI3Kd; IBI-351, einen KRASG12C-Inhibitor; IBI-344, einen Repressor von Silencing 1/TRK-Tyrosinkinase-Inhibitor; IBI-126, ein ADC, das auf CEACAM5 abzielt; IBI-306, ein neuartiger monoklonaler Antikörper gegen das Enzym Protein-Convertase-Subtilisin/Kexin Typ 9; IBI-362, ein dualer Agonist des Glucagon-ähnlichen Peptid-1-Rezeptors/Glucagon-Rezeptors; und IBI-112, ein neuartiges lang wirkendes Anti-IL-23.

Innovent Biologics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Innovent Biologics im Vergleich zum Marktanteil des Unternehmens?
1801 grundlegende Statistiken
Marktanteil	HK$60.60b
Gewinn(TTM)	-HK$1.38b
Umsatz(TTM)	HK$8.01b

7.6x

Kurs-Umsatz-Verhältnis

-44.0x

Kurs-Gewinn-Verhältnis

Ist 1801 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
1801 Gewinn- und Verlustrechnung (TTM)
Einnahmen	CN¥7.46b
Kosten der Einnahmen	CN¥2.12b
Bruttogewinn	CN¥5.34b
Sonstige Ausgaben	CN¥6.62b
Umsatz	-CN¥1.28b

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.78
Bruttomarge	71.58%
Nettogewinnspanne	-17.18%
Schulden/Eigenkapital-Verhältnis	25.8%

Wie hat sich 1801 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

1801 Aktienübersicht

Belohnungen

Risikoanalyse

Innovent Biologics, Inc. Wettbewerber

SEHK:6990

HK$37.4b

SEHK:6826

HK$13.9b

SEHK:9995

HK$16.1b

SEHK:9926

HK$64.8b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Co-Founder recently sold HK$81m worth of stock

First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023)

Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA

Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023)

Recent updates

Co-Founder recently sold HK$81m worth of stock

First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023)

Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA

Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023)

Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China

The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert

Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024

Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)

the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc

Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions

Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

High number of new directors

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Co-Founder recently sold HK$37m worth of stock

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022)

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022)

Now 20% undervalued

Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer

Now 25% undervalued after recent price drop

Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump

Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease

Forecast to breakeven in 2025

Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee

Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?

Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints

Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues

China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib

Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351

Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib

Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care

The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients

Now 20% undervalued

Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor)

Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion.

An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued

First half 2023 earnings: EPS and revenues exceed analyst expectations

National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo

Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting

Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC

Erträge & Einnahmen